DCOY News
Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV
(RTTNews) - Tuesday, Decoy Therapeutics (DCOY) said preclinical pharmacokinetic data support once-weekly intranasal dosing of its lead program DCOY-CoV, designed to protect against endemic human coronaviruses...
Nasdaq News: Markets
Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV
(RTTNews) - Tuesday, Decoy Therapeutics (DCOY) said preclinical pharmacokinetic data support once-weekly intranasal dosing of its lead program DCOY-CoV, designed to protect against endemic human coronaviruses...
Nasdaq News: Markets
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV ProgramPR NewswireCAMBRIDGE, Mass., Sept. 29, 2026 Once-Weekly Intranasal Potential...
PR Newswire
Catalysts Keeping Momentum Going
Today’s tape is driven by catalysts; from a proposed balance-sheet reset at Beneficient (NASDAQ:BENF) to others for Wheeler REIT (NASDAQ:WHLR), Decoy Therapeutics (NASDAQ:DCOY), Greenland Mines Ltd. (NASDAQ:GRML), NeOnc Technologies Holdings (NASDAQ:NTHI), Professional Diversity Network (NASDAQ:IPDN), and Maison Solutions (NASDAQ:MSS).
24-7 Market News
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleasePR NewswireHOUSTON, Sept. 22, 2026 HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY)(the...
PR Newswire
Stocks Riding Compelling Catalysts
Among the listings positioned for strong sessions are Rain Enhancement Technologies (NASDAQ:RAIN), Butterfly Network (NYSE:BFLY), NeOnc Technologies Holdings (NASDAQ:NTHI), Surgery Partners (NASDAQ:SGRY), Omeros (NASDAQ:OMER), Ginkgo Bioworks (NYSE:DNA), and bioAffinity (NASDAQ:BIAF). Meanwhile, Decoy Therapeutics (NASDAQ:DCOY), Filana Therapeutics (NASDAQ:FLNA), Jaguar Health (NASDAQ:JAGX), Maze Therapeutics (NASDAQ:MAZE), Viking Therapeutics (NASDAQ:VKTX), Greenland Mines (NASDAQ:GRML), and Lianhe Sowell International (NASDAQ:LHSW) remain squarely on the market's high-catalyst radar.
24-7 Market News
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq RulesPR...
PR Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers
Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million.
Greenland Mines (NASDAQ:GRML) shares rose 39.21% toread more...
Benzinga
Ebola Surprise Puts Decoy’s AI Antiviral Platform on a Much Bigger Stage
Decoy Therapeutics (NASDAQ:DCOY) is suddenly talking about viruses far beyond the respiratory diseases at the center of its original development strategy, as an unexpected laboratory result could open an entirely new biodefense opportunity.
24-7 Market News
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive FundingPR NewswireCAMBRIDGE, Mass., Sept. 22, 2026 Next-Generation D-MAVs Demonstrate Potent In...
PR Newswire
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMPACT Platform PR Newswire CAMBRIDGE, Mass., Aug. 3, 2026 Portfolio now...
PR Newswire